On Friday, October 13, 2023, our Managing Director Ms. Jennifer Che participated as a panelist in InvestHK’s event “Unlock the Life & Health Sciences Potential through Innovation”. Keynote speeches focused on Hong Kong’s strengths in the life sciences (good medical schools, strong research) and also Hong Kong’s challenges bridging the gap between fundamental research and commercial products. The panel discussion centered around “Hong Kong as a life and health technology innovation hub.” Moderated by Dr. Josephine Au from InvestHK, the other panel members included Ir. Eric Chan from Hong Kong Cyberport Management Co. Ltd., Dr. Grace Lau from HKSTP Institute of Translational Research, Ms. Simone Song from ORI Capital and Mr. Henry Yau from HKU Clinical Trials Centre. Jennifer shared about Hong Kong’s uniqueness as a place to find IP experts having international qualifications as well as cross-border experience. She also expressed frustration at how many HK companies still don’t value the importance of good IP strategy (and are unwilling to invest in such matters), which hurts them when they enter the international stage down the road. It was an enlightening discussion and valuable to hear various people’s thoughts on the future of Hong Kong in the life & health sciences area.
我们的过去活动
Recommended Insights
CHINA: How Prohibiting "Illegal" Inventions Runs into Food Safety Law
2021年10月22日Chinese Patent Law has an interesting provision that specifically prohibits patent protection on “illegal” or “immoral” inventions. What does this mean, exactly? According to Article 5.1 of the Chinese Patent Law, “no patent shall be granted for an invention that contravenes any law or social moral or that is detrimental to public interests.” On its […]
阅读更多 >
Breaking News: Newest Draft Amendment to the Chinese Patent Law Available for Public Comment
2020年7月10日Finally, after more than a year since the last draft amendment came out in 2019, a new draft has been submitted to the National People’s Congress Standing Committee for deliberation on June 28, 2020. The newest version is now published for public comments until August 16, 2020. As a whole, these proposed changes address a […]
阅读更多 >
China Divisional Practice
2019年6月17日China allows the filing of divisional applications but under specific circumstances. Most importantly, divisional applications can usually only be filed voluntarily during the prosecution of the original parent application. Once the parent application is granted or withdrawn, no additional voluntary divisional applications may be filed. However, divisionals can be filed to pursue subject matter not […]
阅读更多 >
China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)
2021年4月30日This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]
阅读更多 >